Crosstalk between gut microbiota and antidiabetic drug action
- PMID: 30891151
- PMCID: PMC6422856
- DOI: 10.4239/wjd.v10.i3.154
Crosstalk between gut microbiota and antidiabetic drug action
Abstract
Type 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due to insulin resistance and unregulated insulin secretion but with tendency towards global spreading. The gut microbiota is recognized to have an influence on T2D, although surveys have not formed a clear overview to date. Because of the interactions between gut microbiota and host homeostasis, intestinal bacteria are believed to play a large role in various diseases, including metabolic syndrome, obesity and associated disease. In this review, we highlight the animal and human studies which have elucidated the roles of metformin, α-glucosidase inhibitors, glucagon-like peptide-1 agonists, peroxisome proliferator-activated receptors γ agonists, inhibitors of dipeptidyl peptidase-4, sodium/glucose cotransporter inhibitors, and other less studied medications on gut microbiota. This review is dedicated to one of the most widespread diseases, T2D, and the currently used antidiabetic drugs and most promising new findings. In general, the gut microbiota has been shown to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, T2D, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing inflammation.
Keywords: Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 agonists; Gut microbiota; Metformin; Peroxisome proliferator-activated receptors γ agonists; Sodium/glucose cotransporter inhibitors; Type 2 diabetes; α-glucosidase inhibitors.
Conflict of interest statement
Conflict-of-interest statement: No potential conflicts of interest.
Figures
Similar articles
-
Gut Microbiota and Antidiabetic Drugs: Perspectives of Personalized Treatment in Type 2 Diabetes Mellitus.Front Cell Infect Microbiol. 2022 May 31;12:853771. doi: 10.3389/fcimb.2022.853771. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35711668 Free PMC article. Review.
-
Persistence to Treatment with Novel Antidiabetic Drugs (Dipeptidyl Peptidase-4 Inhibitors, Sodium-Glucose Co-Transporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists) in People with Type 2 Diabetes: A Nationwide Cohort Study.Diabetes Ther. 2018 Oct;9(5):2133-2141. doi: 10.1007/s13300-018-0483-4. Epub 2018 Aug 17. Diabetes Ther. 2018. PMID: 30120754 Free PMC article.
-
Diabetes and branched-chain amino acids: What is the link?J Diabetes. 2018 May;10(5):350-352. doi: 10.1111/1753-0407.12645. Epub 2018 Feb 13. J Diabetes. 2018. PMID: 29369529
-
How to fight obesity with antidiabetic drugs: targeting gut or kidney?Minerva Endocrinol. 2015 Mar;40(1):71-83. Epub 2014 Nov 4. Minerva Endocrinol. 2015. PMID: 25366984 Review.
-
Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.EBioMedicine. 2019 Jun;44:665-674. doi: 10.1016/j.ebiom.2019.03.057. Epub 2019 Mar 26. EBioMedicine. 2019. PMID: 30922964 Free PMC article.
Cited by
-
Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.Front Endocrinol (Lausanne). 2020 Sep 23;11:573891. doi: 10.3389/fendo.2020.573891. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33071980 Free PMC article.
-
Effects of metformin, acarbose, and sitagliptin monotherapy on gut microbiota in Zucker diabetic fatty rats.BMJ Open Diabetes Res Care. 2019 Sep 20;7(1):e000717. doi: 10.1136/bmjdrc-2019-000717. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31641523 Free PMC article.
-
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer.Cancers (Basel). 2020 Dec 25;13(1):43. doi: 10.3390/cancers13010043. Cancers (Basel). 2020. PMID: 33375686 Free PMC article. Review.
-
Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.Int J Mol Sci. 2020 Sep 22;21(18):6969. doi: 10.3390/ijms21186969. Int J Mol Sci. 2020. PMID: 32971941 Free PMC article. Review.
-
Unveiling the Therapeutic Potential of Berberine in Rheumatoid Arthritis: A Comprehensive Study of Network Pharmacology, Metabolomics, and Intestinal Flora.J Inflamm Res. 2024 Dec 10;17:10849-10869. doi: 10.2147/JIR.S493892. eCollection 2024. J Inflamm Res. 2024. PMID: 39677295 Free PMC article.
References
-
- Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. - PubMed
-
- Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103. - PubMed
Publication types
LinkOut - more resources
Full Text Sources